Breaking news

Will AI Replace Human Creativity In The Gaming Industry?

As artificial intelligence (AI) continues to permeate various sectors, it brings both opportunities and concerns. In the gaming industry, where innovation and creativity are paramount, the question of whether AI might replace human workers is gaining attention.

In a recent interview with the BBC, PlayStation executives Hermen Hulst and Hideaki Nishino emphasized that while AI is transforming game development, it will not replace human creativity. Hulst, CEO of Sony Interactive Entertainment, assured that AI’s role will be to enhance rather than eliminate the human touch in game creation. Nishino echoed this sentiment, pointing to a future where the industry embraces both advanced AI-driven tools and handcrafted, artistic game design.

A Sector Undergoing Transformation

Sony Interactive Entertainment, one of the industry’s giants with a market capitalization exceeding $107 billion as of March 2024, reflects this balance in its strategy. The company has been navigating a dynamic landscape, marked by the success of its PlayStation 5 console and challenges like job cuts affecting the wider industry.

The gaming sector has faced a slowdown in demand since the COVID-19 pandemic, leaving developers to grapple with economic pressures. At the same time, AI advancements are introducing automation to tasks like animation, testing, and procedural world-building. Despite these changes, Sony remains steadfast in its belief that technology cannot replace the artistry and intuition of human game developers.

The Road Ahead

The industry is likely to pursue a hybrid approach in the coming years, leveraging AI to optimize workflows while preserving the human creativity that drives memorable gaming experiences. Developers will still play a critical role in crafting unique and emotionally resonant content, ensuring that the “soul” of gaming remains intact.

As the gaming sector adapts to these shifts, the synergy between human ingenuity and AI innovation could pave the way for groundbreaking advancements, securing a future where both coexist harmoniously.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Uol
eCredo
Aretilaw firm
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter